Jan 12 2026 Mirador Accelerates Multi-Asset Clinical Pipeline in Immuno-Fibrotic Disease; Closes $250 Million Series B with Premier Investors Nov 20 2024 23andMe and Mirador Therapeutics Enter Into Strategic Research Collaboration to Advance Mirador’s Precision Medicines for Immunology & Inflammation Sep 27 2024 Endpoints News Names Mirador Therapeutics a 2024 “Endpoints 11” Winner Mar 21 2024 Mirador Therapeutics Launches to Accelerate the Next Generation of Precision Medicines for Immune-mediated Diseases